PhaseBio Reports First-Quarter 2021 Financial Results and Recent Business Highlights
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
- ServiceNow (NOW) Misses Q3 EPS by 2c, Beats on Revenue; Offers Q4 Revenue Guidance
- Oracle sets $225 billion revenue target for FY30 at investor day
- Amazon (AMZN) Misses Q3 EPS by 7c, Misses on Revenue; Offers Q4 Revenue Guidance
- Six killed in cyclone off India's eastern coast
- Rivian shares slip ahead of Thursday earnings release
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
PhaseBio Pharmaceuticals Inc. (PHAS) PT Lowered to $16 at Needham & Company
May 14, 2021 1:51 PM EDTNeedham & Company analyst Chad Messer lowered the price target on PhaseBio Pharmaceuticals Inc. (NASDAQ: PHAS) to $16.00 (from $19.00) while maintaining a Buy rating.
The analyst commenetd, "In March, PhaseBio announced enrollment in the Phase III REVERSE-IT trial was running ahead of schedule, enrolling... More



